Targeting SHP2 reverses BRAF inhibitor tolerance in anaplastic thyroid carcinoma.

Tang, Tao; Zhou, Jie; Zhang, Li-Xin; Yang, Gang; Li, Wei-Nan; Zhu, Jian-Jiao; Xiong, Yong-Fu; Li, Jing-Dong

Tang, Tao; Zhou, Jie; Zhang, Li-Xin; Yang, Gang; Li, Wei-Nan; Zhu, Jian-Jiao; Xiong, Yong-Fu; Li, Jing-Dong.

Afiliación

Tang T; Affiliated Hospital of North Sichuan Medical College The First Department of Hepatobiliary Surgery Nanchong China.
Zhou J; Affiliated Hospital of North Sichuan Medical College The First Department of Hepatobiliary Surgery Nanchong China.
Zhang LX; Affiliated Hospital of North Sichuan Medical College The First Department of Hepatobiliary Surgery Nanchong China.
Yang G; Affiliated Hospital of North Sichuan Medical College The First Department of Hepatobiliary Surgery Nanchong China.
Li WN; Affiliated Hospital of North Sichuan Medical College The First Department of Hepatobiliary Surgery Nanchong China.
Zhu JJ; Affiliated Hospital of North Sichuan Medical College The First Department of Hepatobiliary Surgery Nanchong China.
Xiong YF; Affiliated Hospital of North Sichuan Medical College The First Department of Hepatobiliary Surgery Nanchong China.
Li JD; Affiliated Hospital of North Sichuan Medical College The First Department of Hepatobiliary Surgery Nanchong China.

Anticancer Agents Med Chem ; 2023 Feb 14.

Article en En | MEDLINE | ID: mdl-36786145

Palabras clave

Anaplastic thyroid carcinoma; BRAF inhibitor; Combination; SHP099; Therapeutic strategy; Tolerance

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Anticancer Agents Med Chem Asunto de la revista: ANTINEOPLASICOS / QUIMICA Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google